Used in pharmaceutical research as a potent and selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK9, which plays a key role in transcription regulation. This compound shows promise in oncology for disrupting cancer cell proliferation by inhibiting RNA polymerase II phosphorylation, thereby suppressing the expression of anti-apoptotic proteins like Mcl-1. It is investigated for its antitumor activity in hematological malignancies, including leukemia and lymphoma. Its imidazopyridine core enhances binding affinity and selectivity, making it a valuable scaffold in developing targeted cancer therapies. Also employed as a chemical probe to study transcriptional control in cellular models.